Exosome Injections: Are They Legal and Safe?

Exosome injections are marketed as shots or IV drips that place exosomes — particles that published studies have derived from human cells or plants — into or under the skin, or into a vein.

People run into the term in a few forms: an "exosome shot" for the face, injectable exosomes marketed for under the eyes, and IV exosome drips.

All of them start from the same fact: FDA states there are currently no FDA-approved exosome products, so there is no exosome product that comes to the syringe with an FDA approval behind it.

That holds whichever route the product takes and whatever the menu calls it — a skin-quality treatment, a regenerative treatment or an "exosome booster".

If you are instead looking at exosome serums applied to the skin's surface, or exosomes paired with microneedling, our exosome treatment guide covers those routes; this page stays with the injected ones.

FDA's position is written down in a consumer alert and a Public Safety Notification.

The consumer alert states that exosome products intended to treat diseases or conditions in humans require FDA approval, and that there are currently no FDA-approved exosome products; the alert is dated July 22, 2020, with content current as of 04/09/2024.

The agency's Public Safety Notification carries the regulatory language: exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products that require premarket review and approval — and FDA calls clinics' claims that exosomes fall outside those rules "simply untrue".

The safety record behind that position is the December 6, 2019 Public Safety Notification, issued after multiple serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes.

The notification does not describe how those products were given or the clinical details behind the events, so it is a warning about unapproved exosome products rather than a documented record of injection injuries specifically.

On the legal question in this page's title: whether any particular clinic's injection is lawful depends on the product involved and its intended use, and we cannot rule on a specific practice from here.

What FDA's public position establishes is the floor — the product in the syringe has no FDA approval, because no exosome product does.

The human studies we could confirm are of the other route.

A 2026 scoping review in Aesthetic Surgery Journal found only 18 human studies of topical exosomes for skin rejuvenation, from 2,394 articles screened, using both human- and plant-derived exosomes.

It concluded that human evidence is scarce and that commercial products gave minimal information on exosome isolation, processing or shelf life.

We could not confirm, in the sources we reviewed, comparable published human studies of exosomes injected for cosmetic skin purposes.

Topical exosome products are typically sold as cosmetics, and cosmetics do not go through FDA premarket approval — so the studied route is not an approved-drug route either.

What differs with injection is the delivery: a needle places the material below the skin surface rather than on it.

There is no approved product for either route, and we found no evidence comparing the safety of one against the other.

If the serum is instead worked in with microneedling, that pairing has its own guide — FDA says microneedling devices are not approved for delivering cosmetics, drugs or other substances into the skin, and our microneedling with exosomes page covers the combination.

FDA's advice to patients considering an exosome treatment comes down to two questions: ask whether the FDA has reviewed the treatment, and ask the clinical investigator for the FDA-issued Investigational New Drug (IND) number.

FDA adds that legitimate trials require signed informed consent overseen by an Institutional Review Board.

Beyond those two questions, other claims are worth weighing against the agency's public position — the exosome-specific versions of broader med spa red flags:

• The product is described as "FDA-approved", "FDA-cleared" or "FDA-registered" — FDA states there are currently no FDA-approved exosome products, so a claim like that does not match the agency's public position.
• The practice says exosomes sit outside the rules for drugs and biological products — FDA calls that claim "simply untrue".
• You are told it is a study or a trial, but no IND number and no informed consent paperwork appear — FDA says legitimate trials require signed informed consent overseen by an Institutional Review Board.
• Nobody can tell you exactly what vial is being opened, who makes it, or what documentation comes with it.

"Safer" is a strong word for any cosmetic injection, so here is the comparison this page can actually support: at least one injectable skin product holds an FDA approval for the specific use it is sold for, with a label you can read.

Exosome injections do not — no exosome product does.

SkinVive is one such product: Skinvive by Juvéderm is an intradermal hyaluronic acid treatment approved in May 2023 to improve cheek skin smoothness and, since June 2026, to reduce neck lines, in adults over 21.

Allergan says results last 6 months with optimal treatment.

Its labeling lists the most common side effects — redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration and itching — most resolving within 7 days.

An approval is not a promise of no side effects; it means FDA reviewed that specific use.

Scope matters as much as approval.

SkinVive is not approved for lips or under-eyes, and an exosome injection under the eyes has no approval behind it at all.

If the under-eye area is your concern, that is a question for a licensed provider who can examine it — not something to hand to an unapproved product because the menu lists one.

The published human studies this page could confirm are of the topical route, and even there the evidence is early: 18 human studies, scarce human evidence, and commercial products with minimal information on isolation, processing or shelf life.

What — if anything — makes sense for your skin is not a decision for a web page.

A licensed provider who can examine your skin is the right person to ask.